Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 22

1.

Interlaboratory concordance of PD-L1 immunohistochemistry for non-small-cell lung cancer.

Scheel AH, Baenfer G, Baretton G, Dietel M, Diezko R, Henkel T, Heukamp LC, Jasani B, Jöhrens K, Kirchner T, Lasitschka F, Petersen I, Reu S, Schildhaus HU, Schirmacher P, Schwamborn K, Sommer U, Stoss O, Tiemann M, Warth A, Weichert W, Wolf J, Büttner R, Rüschoff J.

Histopathology. 2018 Feb;72(3):449-459. doi: 10.1111/his.13375. Epub 2017 Nov 21.

PMID:
28851100
2.

Impact of updated HER2 testing guidelines in breast cancer--re-evaluation of HERA trial fluorescence in situ hybridization data.

Stoss OC, Scheel A, Nagelmeier I, Schildhaus HU, Henkel T, Viale G, Jasani B, Untch M, Rüschoff J.

Mod Pathol. 2015 Dec;28(12):1528-34. doi: 10.1038/modpathol.2015.112. Epub 2015 Sep 25.

3.

HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer.

Van Cutsem E, Bang YJ, Feng-Yi F, Xu JM, Lee KW, Jiao SC, Chong JL, López-Sanchez RI, Price T, Gladkov O, Stoss O, Hill J, Ng V, Lehle M, Thomas M, Kiermaier A, Rüschoff J.

Gastric Cancer. 2015 Jul;18(3):476-84. doi: 10.1007/s10120-014-0402-y. Epub 2014 Jul 20.

4.

Human epidermal growth factor receptor 2 overexpression and amplification in endoscopic biopsies and resection specimens in esophageal and junctional adenocarcinoma.

van Hagen P, Biermann K, Boers JE, Stoss O, Sleddens HF, van Lanschot JJ, Dinjens WN, Rueschoff J, Wijnhoven BP.

Dis Esophagus. 2015 May-Jun;28(4):380-5. doi: 10.1111/dote.12204. Epub 2014 Mar 10.

PMID:
24611982
5.

HER2 staining intensity in HER2-positive disease: relationship with FISH amplification and clinical outcome in the HERA trial of adjuvant trastuzumab.

Zabaglo L, Stoss O, Rüschoff J, Zielinski D, Salter J, Arfi M, Bradbury I, Dafni U, Piccart-Gebhart M, Procter M, Dowsett M; HERA Trial Study Team.

Ann Oncol. 2013 Nov;24(11):2761-6. doi: 10.1093/annonc/mdt275. Epub 2013 Jul 25.

PMID:
23894039
6.

[Her2 testing in gastric cancer. What is different in comparison to breast cancer?].

Rüschoff J, Nagelmeier I, Baretton G, Dietel M, Höfler H, Schildhaus HU, Büttner R, Schlake W, Stoss O, Kreipe HH.

Pathologe. 2010 May;31(3):208-17. doi: 10.1007/s00292-010-1278-1. German.

PMID:
20443098
7.

Disease-free survival according to degree of HER2 amplification for patients treated with adjuvant chemotherapy with or without 1 year of trastuzumab: the HERA Trial.

Dowsett M, Procter M, McCaskill-Stevens W, de Azambuja E, Dafni U, Rueschoff J, Jordan B, Dolci S, Abramovitz M, Stoss O, Viale G, Gelber RD, Piccart-Gebhart M, Leyland-Jones B.

J Clin Oncol. 2009 Jun 20;27(18):2962-9. doi: 10.1200/JCO.2008.19.7939. Epub 2009 Apr 13.

8.

[ErbB2 diagnostics in breast cancer--an update].

Rüschoff J, Nagelmeier I, Hofmann M, Henkel T, Stoss O.

Pathologe. 2009 Mar;30(2):147-55. doi: 10.1007/s00292-009-1126-3. German.

PMID:
19214513
9.

Assessment of a HER2 scoring system for gastric cancer: results from a validation study.

Hofmann M, Stoss O, Shi D, Büttner R, van de Vijver M, Kim W, Ochiai A, Rüschoff J, Henkel T.

Histopathology. 2008 Jun;52(7):797-805. doi: 10.1111/j.1365-2559.2008.03028.x. Epub 2008 Apr 18.

PMID:
18422971
10.

[Her-2/neu analysis--new data?].

Gaiser T, Hofmann M, Stoss O, Henkel T, Rüschoff J.

Verh Dtsch Ges Pathol. 2006;90:107-13. German.

PMID:
17867586
11.

Transcriptional profiling of transurethral resection samples provides insight into molecular mechanisms of hormone refractory prostate cancer.

Stoss O, Werther M, Zielinski D, Middel P, Jost N, Rüschoff J, Henkel T, Albers P.

Prostate Cancer Prostatic Dis. 2008;11(2):166-72. Epub 2007 Jul 24.

PMID:
17646850
12.

[Gene expression profile in hormone refractory prostate cancer].

Stoss O, Jost N, Czeloth K, Rüschoff J, Henkel T, Albers P.

Urologe A. 2007 Sep;46(9):1117-9. German. No abstract available.

PMID:
17639295
13.

Central HER2 IHC and FISH analysis in a trastuzumab (Herceptin) phase II monotherapy study: assessment of test sensitivity and impact of chromosome 17 polysomy.

Hofmann M, Stoss O, Gaiser T, Kneitz H, Heinmöller P, Gutjahr T, Kaufmann M, Henkel T, Rüschoff J.

J Clin Pathol. 2008 Jan;61(1):89-94. Epub 2007 Apr 5.

PMID:
17412870
14.

Expression of the high-affinity fluoropyrimidine-preferring nucleoside transporter hCNT1 correlates with decreased disease-free survival in breast cancer.

Gloeckner-Hofmann K, Guillén-Gómez E, Schmidtgen C, Porstmann R, Ziegler R, Stoss O, Casado FJ, Rüschoff J, Pastor-Anglada M.

Oncology. 2006;70(3):238-44. Epub 2006 Jul 12.

PMID:
16837820
15.

p59(fyn)-mediated phosphorylation regulates the activity of the tissue-specific splicing factor rSLM-1.

Stoss O, Novoyatleva T, Gencheva M, Olbrich M, Benderska N, Stamm S.

Mol Cell Neurosci. 2004 Sep;27(1):8-21.

PMID:
15345239
16.

Emerging therapeutic targets in chronic heart failure: part II.

Roenicke V, Leclair S, Hoffmann A, Becker M, Szado T, Kirsch T, Stoss O, Navé BT, Henkel T.

Expert Opin Ther Targets. 2003 Feb;7(1):49-59. Review.

PMID:
12556202
17.

Emerging therapeutic targets in chronic heart failure: part I.

Roenicke V, Leclair S, Hoffmann A, Becker M, Szado T, Kirsch T, Stoss O, Navé BT, Henkel T.

Expert Opin Ther Targets. 2002 Dec;6(6):649-58. Review.

PMID:
12472378
18.

An alternative-exon database and its statistical analysis.

Stamm S, Zhu J, Nakai K, Stoilov P, Stoss O, Zhang MQ.

DNA Cell Biol. 2000 Dec;19(12):739-56.

PMID:
11177572
19.

The STAR/GSG family protein rSLM-2 regulates the selection of alternative splice sites.

Stoss O, Olbrich M, Hartmann AM, Konig H, Memmott J, Andreadis A, Stamm S.

J Biol Chem. 2001 Mar 23;276(12):8665-73. Epub 2000 Dec 15.

20.

The in vivo minigene approach to analyze tissue-specific splicing.

Stoss O, Stoilov P, Hartmann AM, Nayler O, Stamm S.

Brain Res Brain Res Protoc. 1999 Dec;4(3):383-94.

PMID:
10592349

Supplemental Content

Support Center